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study question: How potently does the novel hypothalamic stimulator of reproduction, kisspeptin, increase gonadotrophin secretion
when compared with GnRH in healthy men?
summaryanswer: At the doses tested, intravenous administration of either of twomajor kisspeptin isoforms, kisspeptin-10 and -54,was
associatedwith similar levels of gonadotrophin secretion in healthymen; however,GnRHwasmorepotentwhencomparedwith either kisspeptin
isoform.
what is known already: Kisspeptin-10 and -54 are naturally occurring hormones in the kisspeptin peptide family which potently sti-
mulates endogenousGnRH secretion from the hypothalamus, so have the potential to treat patients with reproductive disorders. Rodent studies
suggest that kisspeptin-54 is more potent when comparedwith kisspepitn-10; however, their effects have not previously been directly compared
in humans, or compared with direct pituitary stimulation of gonadotrophin secretion using GnRH.
studydesign, size and duration: Asingle-blindedplacebo controlledphysiological studywasperformed from January toDecem-
ber 2013. Local ethical approval was granted, and ﬁve participants were recruited to each dosing group.
participants/materials, setting, methods: Healthy men were administered vehicle, kisspeptin-10, kisspeptin-54 and
GnRH intravenously for 3 h on different study days. Each hormone was administered at 0.1, 0.3 and 1.0 nmol/kg/h doses (n ¼ 5 subjects per
group). Regular blood sampling was conducted throughout the study to measure LH and FSH. Study visits were conducted at least a week apart.
main results and the role of chance: Serum LH and FSH levels were 3-fold higher during GnRH infusion when compared
with kisspeptin-10 and 2-fold higher when compared with kisspeptin-54 [mean area under the curve serum LH during infusion (in hours times
international units per litre, h.IU/l): 10.81+ 1.73, 1.0 nmol/kg/h kisspeptin-10; 14.43+1.27, 1.0 nmol/kg/h kisspeptin-54; 34.06+5.18,
1.0 nmol/kg/h GnRH, P, 0.001 versus kisspeptin-10, P, 0.01 versus kisspeptin-54].
limitations, reasons for caution: This study had a small sample size.
wider implications of the findings: Kisspeptin offers a novel means of stimulating the reproductive axis. Our data suggest that
kisspeptin stimulates gonadotrophin secretion less potently when comparedwith GnRH; however, kisspeptinmay stimulate gonadotrophins in a
more physiological manner when compared with current therapies. Kisspeptin is emerging as a future therapeutic agent, so it is important to es-
tablishwhich kisspeptin hormones could be used to treat patientswith infertility. Results of this study suggest that either isoformhas similar effects
on reproductive hormone secretion in healthy men when administered intravenously.
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Introduction
Ten per cent of couples are infertile, and this proportion is likely to rise
due to the increasing age of couples attempting pregnancy within eco-
nomically developed countries (NHS Choices, 2014). There is, there-
fore, an urgent need to develop novel therapeutic avenues for treating
patients with infertility. Kisspeptin is a group of recently identiﬁed
RF-amide peptide hypothalamic hormones which are currently being
evaluated as potential novel therapies for infertility (Ohtaki et al.,
2001). Kisspeptin hormones are essential for human fertility and act by
stimulating GnRH release (Ohtaki et al., 2001). Inactivating mutations
in the kisspeptin signalling pathway cause pubertal failure, and activating
mutations cause precocious puberty (de Roux et al., 2003; Seminara
et al., 2003;Teles et al., 2008;Topaloglu et al., 2012). Exogenous kisspep-
tin potently stimulates the secretion of the pituitary gonadotrophin hor-
mones (LH and FSH) in numerous mammalian species including rats
(Irwig et al., 2004), mice (Gottsch et al., 2004), sheep (Caraty et al.,
2007), cows (Kadokawa et al., 2008), monkeys (Shahab et al., 2005)
and humans (Dhillo et al., 2005, 2007; Jayasena et al., 2009, 2010;
Chan et al., 2011, 2012;George et al., 2011; Young et al., 2013). Kisspep-
tin hasbeen administered tohuman subjectswithout any signiﬁcant acute
or chronic adverse effects.
Furthermore, we have recently demonstrated that exogenous
kisspeptin-54 can stimulate egg maturation in women with infertility
undergoing in vitro fertilization treatment (Jayasena et al., 2014), and
Phase 2 studies are currently underway evaluating the effects of the kis-
speptin analogue, TAK-448, on reproductive hormone secretion in
healthy men (MacLean et al., 2014). Kisspeptin is, therefore, a newly dis-
covered family of hormones which is the subject of intense clinical inves-
tigation for its potential role in the treatment of patients with infertility.
Members of the kisspeptin family share a common binding site to the
kisspeptin receptor and are denoted by amino acid length (Ohtaki et al.,
2001). Unfortunately, early human studies investigating the effect of kis-
speptin on the reproductive system have used either kisspeptin-10 or
kisspeptin-54 (full-length kisspeptin), but not both isoforms.This is prob-
lematic, since clinically important differences are likely to exist between
kisspeptin-10 and -54. First, kisspeptin-54 has been observed to stimu-
late gonadotrophin secretion when administered through the subcuta-
neous or intravenous routes in all subject groups tested (Dhillo et al.,
2005, 2007; Jayasena et al., 2009, 2010). Several studies suggest that
Kisspeptin-10 stimulates gonadotrophin secretion when administered
intravenously (Chan et al., 2011; George et al., 2011; Jayasena et al.,
2011), but one study failed to observe a signiﬁcant stimulation of
gonadotrophin secretion following subcutaneous bolus injection of
kisspeptin-10 to healthy women during the follicular phase of menstrual
cycle (Jayasena et al., 2011). Differences between the effects of
kisspeptin-10 and -54 may be related to our previous observations
that the plasma half-live of kisspeptin-10 is 6-fold shorter when
compared with kisspeptin-54 (Dhillo et al., 2005; Jayasena et al.,
2011). In addition, the shorter amino acid sequence of kisspeptin-10
makes it far less expensive to synthesize when compared with
kisspeptin-54. Various dosing regimens and human models have been
evaluatedduring previous clinical studies; accordingly, the relative poten-
cies of kisspeptin-10 and -54 stimulating gonadotrophin secretion in
humans remain unknown. Furthermore, it is not known how potently
kisspeptin-10 and -54 stimulate gonadotrophin secretion in humans
when compared with GnRH, which itself may be used to treat patients
with infertility. Establishing the potencies of kisspeptin hormones is
important for the future development of kisspeptin-based therapies to
treat patients with infertility.
We performed a single-blinded placebo controlled study to compare
directly for the ﬁrst time, the effects kisspeptin-10, kisspeptin-54 and
GnRH on gonadotrophin secretion in healthy male volunteers, when
administered at equimolar doses using a constant 3 h intravenous infu-
sion regimen.
Materials andMethods
Ethical approval
Ethical approval was granted by the Local Ethics Research Committee (regis-
tration: 12LO/0507). Written informed consent was obtained from all sub-
jects. This study was performed in accordance with the Declaration of
Helsinki.
Subjects
Ten healthy male volunteers were recruited through advertisements in local
newspapers. Responders to adverts were evaluated with a detailed medical
history, clinical examination, electrocardiogram and blood tests as follows:
full blood count, renal proﬁle, liver proﬁle, bone proﬁle, random glucose,
thyroid proﬁle, LH, FSH, testosterone and sex hormone-binding globulin.
Participants were included within the study if they fulﬁlled the following cri-
teria: age between 18 and 45 years, absence of signiﬁcant systemic disease
co-morbidity, absenceof therapeutic or recreational drug use, normal clinical
andbiochemical reproductive function, absenceof blooddonation in thepre-
ceding 3 months. Ten subjects participated in the study, with a summary of
baseline characteristics provided in Table I.
Peptides
Gonadorelin 100 mg (GnRH) was purchased from Intrapharm laboratories
Ltd (Maidenhead, Berks, UK). It was reconstituted with the sterile solvent
supplied containing 2% benzyl alcohol and water for injection. Kisspeptin-10
and kisspeptin-54were synthesizedbyBachemUK (Liverpool, UK). Both kis-
speptin isoforms were puriﬁed and tested as described previously (Dhillo
et al., 2005; Jayasena et al., 2011). Vials of freeze-dried kisspeptin were
stored at 2208C and reconstituted in 0.5 ml of 0.9% saline.
Study protocol
Patients were admitted to our clinical investigation unit in the morning and
asked to lay supine (seeFig. 1 forprotocol summary). Baselineblood sampling
Kiss-10, kiss-54 and GnRH in men 1935
 at Im
perial College London on A
ugust 27, 2015
http://hum
rep.oxfordjournals.org/
D
ow
nloaded from
 
was performed at 10 min intervals between 0 and 60 min. A single-blinded
3 h continuous intravenous infusion of gelofusin (vehicle), kisspeptin-10
(0.10, 0.30 or 1.00 nmol/kg/h), kisspeptin-54 (0.10, 0.30 or 1.00 nmol/
kg/h) or GnRH (0.10, 0.30 or 1.00 nmol/kg/h) was commenced at time
60 min and continued until 240 min (n ¼ 5 subjects per group; see Table II
for dose allocation of subjects). The doses selected during this study were
basedonprevious studies that have demonstrated an LH rise during intraven-
ous infusion of kisspeptin-54 in healthy men (Dhillo et al., 2005). A 2-fold
higher infusion ratewas administered during the ﬁrst 30 min of each infusion,
in order to achieve steady-state plasma levels (Edwards et al., 1999). There-
fore, total doses of 0.35, 1.05 or 3.50 nmol/kg peptide were administered
during 3 h infusions with maintenance administration rates of 0.10, 0.30 or
1.00 nmol/kg/h, respectively. Blood samples were taken through a cannula
at 10 min intervals from t ¼ 0 to t ¼ 240 min to measure gonadotrophin
levels. Blood samples were also taken for plasma kisspeptin immunoreactivity
(kisspeptin IR) and at t ¼ 0, 60, 70, 80, 90, 120, 180 and 240 min. Study visits
for individual patients were scheduled a minimum of a week apart and
performed in a random order.
.............................................................................................................................................................................................
Table I Baseline characteristics of study volunteers.
Participant no. Age (years) Weight (kg) BMI (kg/m2) LH (IU/l) FSH (IU/l) Testosterone (nmol/l)
1 25 75.9 26.5 4.40 2.21 18.78
2 23 82.7 24.1 4.69 2.67 31.40
3 34 73.1 23.9 5.16 4.25 16.05
4 20 68.4 23.6 2.11 1.85 23.97
5 28 88.4 25.7 4.03 3.16 12.29
6 43 66.3 19.8 2.01 2.55 22.91
7 30 68.7 25.2 3.10 2.09 13.65
8 30 62.2 20.2 1.78 1.66 29.75
9 26 71.3 23.4 2.61 2.84 17.05
10 30 83.9 23.7 5.30 1.74 20.52
Mean+ SEM 28.9+2.02 74.10+2.69 23.61+0.68 3.52+0.43 2.50+0.25 20.60+2.03
Figure 1 Protocol diagram for study visits in healthy male subjects. Blood samples taken every 10min from t ¼ 0 to t ¼ 240 min for serum LH and FSH.
Blood samples were also taken for plasma kisspeptin IR at t ¼ 0, 60, 70, 80, 90, 120, 180 and 240 min. After 1 h of baseline blood sampling, the infusions of
vehicle, kisspeptin-10, kisspeptin-54 or GnRHwere commenced. Maintenance infusion doses were 0.1, 0.3 and 1.0 nmol/kg/h of each peptide. Each par-
ticipant received the same dose of each peptide in random order at least 1 week apart (n ¼ 5/group).
........................................................................................
Table II Allocation of healthy men to infusion
treatment groups.
Treatment group Dose Subject number
Vehicle — 2 3 9 10 8
KP10, KP54 or GnRH 0.1 nmol/kg/h 1 4 5 6 7
KP10, KP54 or GnRH 0.3 nmol/kg/h 1 4 7 8 10
KP10, KP54 or GnRH 1.0 nmol/kg/h 2 3 5 6 9
Ten different 3 h intravenous infusions were administered in healthymen: vehicle; 0.1,
0.3 or 1.0 nmol/kg/h kisspeptin-10 (KP10); 0.1, 0.3 or 1.0 nmol/kg/h kisspeptin-54
(KP54); 0.1, 0.3 or 1.0 nmol/kg/h GnRH. In order to directly compare the effects of
equimolar doses of kisspeptin-10, kisspeptin-54 and GnRH, the same combination of
subjects (numbered 1–10) received the same dose of each peptide. Study visits for
individual patients were scheduled a minimum of a week apart and performed in the
random order.
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Analytical methods
Serum LH and FSH levels were measured at all time points using automa-
ted chemiluminescent immunoassays (Abbott Diagnostics, Maidenhead,
UK). Reference ranges for males were as follows: LH 4–14 IU/l; FSH
1.5–8 IU/l. The respective inter-assay coefﬁcients of variation for each
assaywere: 4.1 and 3.4% (LH) and 4.1 and 3.5% (FSH). Analytical sensitivities
were: 0.5 IU/l (LH) and0.05 IU/l (FSH). Limits of detectability for each assay
were: 0.07 IU/l (LH) and 0.05 IU/l (FSH).
Measurement of plasma kisspeptin IR was performed using an established
radioimmunoassay (Dhillo et al., 2005, 2007). The antibody used tomeasure
kisspeptin IR has 100% cross-reactivity with kisspeptin-10 and -54 (Dhillo
et al., 2005).
Statistical methods
Cumulative changes in hormone secretionwerequantiﬁedby calculating area
under the curve (AUC) values using Prism (GraphPad Inc., La Jolla, CA,USA);
mean AUC values for each peptide and dose were compared using two-way
ANOVA with the Bonferroni’s post hoc analysis test. P, 0.05 was consid-
ered statistically signiﬁcant.
Results
Levels of circulating kisspeptin during 3 h
intravenous infusion of kisspeptin-10,
kisspeptin-54 or GnRH
Time proﬁles for plasma kisspeptin IR are presented for vehicle and each
doseof kisspeptin-10, kisspeptin-54andGnRH inhealthymen (Fig. 2A–C),
and cumulative levels of kisspeptin IR (AUC) are also presented (Fig. 2D
and E). As expected, levels of plasma kisspeptin IR were not elevated
signiﬁcantly during intravenous infusion of vehicle or any tested dose
(0.1, 0.3 and1.0 nmol/kg/h)ofGnRH inhealthymen (Fig. 2A–E).Dose-
dependent elevations in plasma kisspeptin IRwere observed during infu-
sion kisspeptin-54 and to a lesser extent during kisspeptin-10 infusion. At
the highest dose (1.0 nmol/kg/h), levels of AUC kisspeptin IR were
37-fold higher during kisspeptin-54 infusion when compared with
kisspeptin-10 and 170-fold higher when compared with vehicle (mean
AUC plasma kisspeptin IR during infusion in h pmol/l: 179+24,
1.0 nmol/kg kisspeptin-10; 6650+ 397, 1.0 nmol/kg kisspeptin-54,
P, 0.001 versus vehicle, P, 0.001 versus 1.0 nmol/kg kisspeptin-10).
Levels of serum LH during 3 h intravenous
infusion of kisspeptin-10, kisspeptin-54 or
GnRH
Time proﬁles for serum LH are presented for vehicle and each dose of
kisspeptin-10, kisspeptin-54 and GnRH in healthy men (Fig. 3A–C), and
cumulative levels of AUC serum LH are also presented (Fig. 3Dand E).
As expected, levels of serum LH were not elevated signiﬁcantly during
intravenous infusion of vehicle in healthy men (Fig. 3A–E). Dose-
dependent elevations in serum LH were observed during infusion of
GnRH and to a lesser extent during kisspeptin-10 and kisspeptin-54 infu-
sions. For all three hormones, peak levels of LH secretion were observed
at the 0.3 nmol/kg/h dose; at this dose, levels of AUC serum LH were
3-fold higher during GnRH infusion when compared with kisspeptin-10
and 2-fold higher when compared with kisspeptin-54 (mean AUC
serum LH during infusion in h IU/l: 10.81+1.73, 1.0 nmol/kg/h
kisspeptin-10; 14.43+1.27, 1.0 nmol/kg/h kisspeptin-54; 34.06+
5.18, 1.0 nmol/kg/h GnRH, P, 0.001 versus kisspeptin-10, P, 0.01
versus kisspeptin-54).
Levels of serum FSH during 3 h intravenous
infusion of kisspeptin-10, kisspeptin-54 and
GnRH
Time proﬁles for serum FSH are presented for vehicle and each dose
of kisspeptin-10, kisspeptin-54 and GnRH in healthy men (Fig. 4A–
C), and cumulative levels of AUC serum LH are also presented
(Fig. 4D and E). As expected, levels of serum FSH were not elevated
signiﬁcantly during intravenous infusion of vehicle in healthy men
(Fig. 4A–E). Dose-dependent elevations in serum FSH were observed
during infusion of GnRH and to a lesser extent during kisspeptin-10
and kisspeptin-54 infusions. Peak levels of FSH secretion during GnRH
were observed at the 1.0 nmol/kg/h dose; at this dose, levels of AUC
serum FSHwere over 3-fold higher duringGnRH infusionwhen compared
with kisspeptin-10 and over 2-fold higher when compared with
kisspeptin-54 (mean AUC increase in serum FSH during infusion in h IU/l:
1.43+0.24, 1.0 nmol/kg/h kisspeptin-10; 1.90+0.22, 1.0 nmol/kg/h
kisspeptin-54, P, 0.01 versus vehicle; 4.69+0.55, 1.0 nmol/kg/h
GnRH, P, 0.001 versus 1.0 nmol/kg/h kisspeptin-10, P, 0.001 versus
1.0 nmol/kg/h kisspeptin-54).
Discussion
Direct stimulation of the hypothalamus using kisspeptin administration
offers an attractive novel potential avenue for treating patientswith infer-
tility, since it causes the release of an endogenous pool ofGnRH,which in
turn stimulates physiological levels of gonadotrophin secretion (Gottsch
et al., 2004;Messager et al., 2005; Shahab et al., 2005). Kisspeptin, there-
fore, stimulates the reproductive axis in a self-limiting manner, which is
more physiological when compared with direct pituitary or gonadal
stimulation with GnRH analogues or gonadotrophin preparations, re-
spectively. Studying the clinical effects of kisspeptin is complicated
by the presence of two major studied isoforms of kisspeptin -10 and
-54, which have differential pharmacokinetic proﬁles, potential routes
of administration and manufacturing costs (Dhillo et al., 2005, 2007;
Chan et al., 2011; George et al., 2011; Jayasena et al., 2011). Further-
more, the effects of neither kisspeptin hormone on gonadotrophin
secretion have been directly compared with the effects of GnRH.
Our data suggest for the ﬁrst time that at the doses tested, GnRH stimu-
lates gonadotrophins more potently when compared with either kis-
speptin hormone in healthy men, but that kisspeptin-10 and -54 have
broadly similar potencies of action. These data have important implica-
tions for the development of future therapies for infertility based upon
kisspeptin.
The effects of the long and short forms of kisspeptin have been com-
pared directly in rodents. Intravenous bolus injection of 3.0 nmol/kg
kisspeptin-52 (the rodent homologue of kisspeptin-54) stimulated
30%more LH secretion in male rats when compared with an equimo-
lar dose of kisspeptin-10 (Tovar et al., 2006). Furthermore, subcutane-
ous bolus injection of 1 or 50 nmol kisspeptin-54 stimulated 6-fold
more LH secretion in male rats when compared with an equimolar
dose of kisspeptin-10 (Thompson et al., 2006). It is interesting to note
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that kisspeptin-10 and -54 infusions were associated with comparable
gonadotrophin responses despite levels of plasmakisspeptin IRbeing sig-
niﬁcantly higher during the kisspeptin-54 infusion. The likely explanation
for this ﬁnding is the much shorter in vitro half-life of kisspeptin-10 of 55 s
(Seminara et al., 2003) and in vivoplasmahalf-life of kisspeptin-10of 4 min
(Jayasena et al., 2011) compared with kisspeptin-54 of 27.6 min (Dhillo
et al., 2005) which would lead to rapid degradation of kisspeptin-10
in comparison with kisspeptin-54. Hence, this difference in half-life
between kisspeptin-10 and -54 would be expected to result in lower
steady-state levels of plasma kisspeptin IR during kisspeptin-10 infusion
compared with kisspeptin-54 infusion as observed in this study.
Kisspeptin-54 has consistently been observed to stimulate gonado-
trophin secretion when administered by subcutaneous bolus injection
in healthy women in each phase of the menstrual cycle, in addition to
women with hypothalamic amenorrhoea (Dhillo et al., 2007; Jayasena
et al., 2009). In contrast, subcutaneous bolus injection of kisspeptin-10
appears not to stimulate gonadotrophin secretion signiﬁcantly in
women during the follicular phase of the menstrual cycle (Jayasena
et al., 2011).However,we cannot exclude the possibility that subcutane-
ous bolus injection of kisspeptin-10 in other human models (e.g. healthy
women during the pre-ovulatory phase of the menstrual cycle and
womenwith hypothalamic amenorrhoea) could result in gonadotrophin
release.
GnRHhas been comparedwith kisspeptin in only a fewanimal studies.
Tovar et al. (2006) found thatmale rats had a greater LH response to i.v.
GnRH compared with equimolar doses of IV kisspeptin-10, when it was
given 120 min after the last pulse of kisspeptin-10 (given every 75 min for
the preceding 450 min). Thompson et al. (2009) showed that a single
50 nmol bolus of s.c. kisspeptin-54 resulted in similar gonadotrophin
release when compared with equimolar doses of GnRH in rats. In
adult female goats in the luteal phase, kisspeptin-10 or GnRH caused a
rise in gonadotrophins; however, GnRH produced a more gradual rise
that achieved greater peak levels of gonadotrophins compared with
kisspeptin-10 when given at the same dose (Hashizume et al., 2010).
Male juvenile rhesus monkeys primed with intermittent IV GnRH
showed that on receiving an IV bolus of kisspeptin-10, their LH pulses
were of similar magnitude to that seen during the preceding GnRH
priming; however, the dose of kisspeptin was almost 10 fold higher
than that of GnRH (Plant et al., 2006).
There are a number of possible reasons why the maximal effects
of kisspeptin-10 or -54 (at 0.3 nmol/kg/h) on LH secretion were
signiﬁcantly lower than the maximal effects of GnRH (at 1.0 nmol/kg/h)
in healthy men. The likely predominant reason is that endogenous
GnRH released by kisspeptin may stimulate a submaximal level of
gonadotrophin secretion from the pituitary. Second, it is possible
that not all kisspeptin can penetrate the hypothalamus from the
Figure2 Plasma kisspeptin IR during intravenous administrationof kisspeptin-10, kisspeptin-54 andGnRH to healthymen. Time proﬁles ofmean plasma
kisspeptin IR are presented during infusion of vehicle, kisspeptin-10 (A), kisspeptin-54 (B) andGnRH (C), at the following doses: 0.1, 0.3 and 1.0 nmol/kg/h.
The infusion period commenced at 60 min and is represented by the grey shaded area. Grey ﬁlled circles, vehicle; orange ﬁlled triangles, 0.1 nmol/kg/h; red
clear circles, 0.3 nmol/kg/h;maroonﬁlled circles, 1.0 nmol/kg/h.MeanAUCplasmakisspeptin IR ispresented foreach infusion group: graphD showsdata as
linearcurvesandgraphEasbar graphs.Vehicle inblack, kisspeptin-10 in red, kisspeptin-54 inblueandGnRHinpurple.Dataarepresentedasthemean+ SEM.
N ¼ 5/group. ***P, 0.001 for GnRH versus kisspeptin-54. FFFP, 0.001 for GnRH versus kisspeptin-10.
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circulation. Kisspeptin has been shown to activate the release of GnRH
from nerve terminals at the median eminence, which lacks a complete
blood brain barrier (bbb) (d’Anglemont de Tassigny et al., 2010).
However, it is not known whether additional saturable transport
mechanisms for kisspeptin exist across the bbb. Finally, the majority
but not all GnRH neurons express the kisspeptin receptor (77% in
adult male rats), which implies that a subset of GnRH neurons lack the
receptor to respond to kisspeptin (Irwig et al., 2004). These factors
clearly contribute to the reduced potency of kisspeptin to stimulate re-
productive function when compared with GnRH; however, one could
speculate whether these same factors also confer a therapeutic advan-
tage over exogenous GnRH, by stimulating a level of gonadotrophin se-
cretion which does not exceed physiological levels. Future studies are
needed to determine if such an action could prevent adverse conse-
quences of excessive gonadotrophin stimulation, such as the ovarian
hyperstimulation syndrome during in vitro fertilization therapy (Elchalal
and Schenker, 1997).
It is important to consider the strengths and weakness of the
study. Each kisspeptin isoform has relative advantages over the other
isoform. For instance, kisspeptin-54 but not kisspeptin-10 can be admi-
nistered subcutaneously due to its long half-life; however, kisspeptin-10
is substantially cheaper to manufacture when compared with kisspep-
tin-54, due to its short amino acid sequence. This study provides the
ﬁrst direct and objective comparison of kisspeptin-10 and -54 adminis-
tration in human subjects. We recognize that this was a small study
primarily aimed to compare the potencies of two novel kisspeptin
hormones with an established stimulator of LH secretion, GnRH.
However, ethical considerations prohibited us from giving vehicle
plus each of the three doses of each three tested hormones to individ-
ual subjects, which may have accounted for some of the observed
variation in data. It would be interesting to extend the duration of
blood sampling following kisspeptin and GnRH infusions beyond 4 h,
in order to accurately compare the levels of sex steroid secretion in
subjects.
In summary, we have directly compared for the ﬁrst time, the effects
of kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion
in healthy men. At the doses tested, intravenous administration
of kisspeptin-10 and -54 was associated with similar levels of
Figure3 Change in serum LH levels during intravenous administration of kisspeptin-10, kisspeptin-54 andGnRH to healthy men. Time proﬁles of mean
change in serum LH are presented during infusion of vehicle, kisspeptin-10 (A), kisspeptin-54 (B) and GnRH (C), at the following doses: 0.1, 0.3 and
1.0 nmol/kg/h. The infusion period commenced at 60 min and is represented by the grey shaded area. Grey ﬁlled circles, vehicle; orange ﬁlled triangles,
0.1 nmol/kg/h; red clear circles, 0.3 nmol/kg/h;maroonﬁlled circles, 1.0 nmol/kg/h.Mean change inAUCserumLH is presented foreach infusion group:
graphD shows data as linear curves and graph E as bar graphs. Vehicle in black; kisspeptin-10 in red; kisspeptin-54 in blue; GnRH in purple. Data are pre-
sented as the mean+ SEM.N ¼ 5/group. *P, 0.05 for GnRH versus KP54. **P, 0.01 for GnRH versus kisspeptin-54. FFFP, 0.001 for GnRH versus
kisspeptin-10.
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gonadotrophin secretion in healthy men, but GnRH was more potent
when compared with either kisspeptin isoform. These data provide im-
portant information for the future development of kisspeptin-based
therapies to treat patients with infertility.
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